How Big Pharma Is King of the Hill in M&A

According to Ernst & Young (EY), 67% of merger & acquisition investment in 2023 came specifically from big pharma, compared to 38% in 2022. A number of deals between healthcare companies have already been announced for 2024, leading to the potential for growth in the category. Arda Ural, EY Americas Industry Markets Leader for Health Sciences and Wellness, sits down with Yahoo Finance Anchor Julie Hyman and Healthcare Reporter Anjalee Khemlani to discuss state of mergers & acquisitions in the healthcare sector and what it may look like going forward.

Read the full article: How Big Pharma Is King of the Hill in M&A //

Source: https://finance.yahoo.com/video/big-pharma-king-hill-m-225153046.html

Leave a Comment

Your email address will not be published.

Scroll to Top